Last reviewed · How we verify
GSK2981278 0.8%
At a glance
| Generic name | GSK2981278 0.8% |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- COMMON COLD
Key clinical trials
- A Study of GSK2981278 Ointment in Subjects With Plaque Psoriasis (PHASE1, PHASE2)
- Study of Safety and Efficacy of Topical GSK2981278 Ointment in Plaque Psoriasis (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GSK2981278 0.8% CI brief — competitive landscape report
- GSK2981278 0.8% updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI